Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Commerzbank Corporate Conference 2021

55 slides from Fresenius SE & Co. KGaA's conference presentation, Aug 31, 2021

  1. Slide 1: Commerzbank Corporate Conference

    Commerzbank Corporate Conference August 31, 2021

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Agenda

    Agenda 02 03 04 01 Strategic update Financial review Attachments Q2/21 & Company Outlook FY/21 Highlights Commerzbank Corporate Conference, August 31, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 3

  4. Slide 4: A Global Leader in Health Care Products and Services

    A Global Leader in Health Care Products and Services in sales Long-term (FY/2020) opportunities in growing, € 36.3 bn non-cyclical markets Global presence Strong financial in 100+ performance countries and cash flow 100 + generation Leading Employees market worldwide positions (as of June 30, 2021)

  5. Slide 5: Investment Highlights

    Investment Highlights Diversified healthcare Group Leading positions in Resilient business model with four strong business growing non-cyclical based on megatrends segments markets healthcare and demographics Purpose-driven business Strong financial Reliable delivers sustainable performance and cash

  6. Slide 6: Global Trends offer Growth Opportunities for Fresenius

    Global Trends offer Growth Opportunities for Fresenius 4x Increasing national income Generic GDP per capita quadrupled Growing drugs over last 20 years in emerging save the US markets and developing healthcare sector Growth in emerging healthcare 293bn +6.3% economies system4 markets over the next p

  7. Slide 7: The Fresenius Strategy

    The Fresenius Strategy Improve profitability Drive Quality Internation- alization Hospital Dialysis supplies & products & Innovation services services Employees Better Hospital projects & medicine and Hospital operations services health care services for ever more people Forward thinking healthcare

  8. Slide 8: Strategic Roadmap

    Strategic Roadmap 3 Operational excellence Growth drivers Accelerate Capital allocation Strategic evaluation Significant cost savings 2 Launch Idacio in US Growth areas: Biosimilars, Fertility, Grow Digital services, Home-hemodialysis First meaningful cost savings Balance sheet flexibility 1 Continu

  9. Slide 9: Growth Areas

    Growth Areas Worldwide growing Growing Markets with Marketing of existing Attractive markets dialysis market High Entry Barriers value chain Strengthening Standardizing Attractive Market and extension medical procedures Product Pipeline consolidation of value chain Home dialysis Entry into attractiv

  10. Slide 10: Environment, Social and Governance: Setting the right priorities in a COVID-19 world

    Environment, Social and Governance Setting the right priorities in a COVID-19 world ESG priorities confirmed Sustainability progress in 2020 Corporate governance update “Better medicine for more people” Rating improvements across the board, New Management Board remuneration Highlights: CDP Climate f

  11. Slide 11: Environment, Social and Governance: Refreshed Materiality analysis

    Environment, Social and Governance Refreshed Materiality analysis in 2020 - core priorities confirmed, new topics added Well-being of the Digital Transformation Employees patient & Innovation  Working conditions, recruitment  Access to health care  Digitilization & Innovation & employee participa

  12. Slide 12: ESG Rating Overview

    ESG Rating Overview Continuous Improvement through Reporting and Engagement CDP Climate: B 50/100 Current Score Prime C+ BBB 17.8 Low Risk CDP Water: C DJSI Europe Rank 6 out of 99 at Sector Average CDP Climate: C C- BBB - A 28 / 100 subindustry level CDP Climate: C Previous Score Prime C BB 39/100

  13. Slide 13: Group: Global Sales Base in Growing, Non-Cyclical Markets

    Fresenius Group: Global Sales Base in Growing, Non-Cyclical Markets 2020 Sales by Region Sales in € bn 6% 35,409 36,277 CAGR 33,886 33,530 Latin America Africa 29,471 4% 1% Asia-Pacific 10% €36.3 bn Europe 4,612 44% 4,830 4,688 4,302 4,561 North America 41% 2016 2017 2018 2019 2020  EBIT Before spe

  14. Slide 14: Strong track record of organic sales growth

    Strong track record of organic sales growth 5% 7% 7% 7% 7% CAGR 5% 5% 4% 4% 4% 6% 6% 3% 5% ´16 ´17 ´18 ´19 ´20 ´16 ´17 ´18 ´19 ´20 4% 3% 16% 16% 4% 6% 5% 5% 4% 4% 3% ´16 ´17 ´18 ´19 ´20 ´16 ´17 ´18 ´19 ´20 -8% ´16 ´17 ´18 ´19 ´20 Shaded areas show estimated COVID-19 effects Commerzbank Corporate Con

  15. Slide 15: Strong and Balanced Health Care Portfolio

    Strong and Balanced Health Care Portfolio Ownership: ~32% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services Health Care Services for Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc

  16. Slide 16: Fresenius Medical Care: Global Dialysis Market Leader

    Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis Sales by Region Market Dynamics products and services treating ~346,000 patients1 in ~4,100 clinics1 Asia-Pacific North America Increase in worldwide demand • Provide highest standard of product and Lati

  17. Slide 17: Fresenius Kabi: A Leading Global Hospital Supplier

    Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for Sales by Region Market Dynamics critically and chronically ill patients • Strong Emerging Markets presence Emerging Markets Growing healthcare spending • Leading market positions 31% in Emerging Markets +6.3% p.

  18. Slide 18: Fresenius Kabi: Entry into attractive biosimilars business

    Fresenius Kabi: Entry into attractive biosimilars business Business Plan Sales Projection Launch schedule Autoimmune Oncology Adalimumab Acquisition of Merck KGaA’s Q1 High triple Q2 Biosimilars Business in 2017 digit € m Introduced in >20 EU countries since launch 2019 Q3 Pegfilgrastim Pre-filled O

  19. Slide 19: Fresenius Helios: Europe's Largest Private Hospital Operator

    Fresenius Helios: Europe’s Largest Private Hospital Operator • Market leader in size and quality with Sales by Region Market Dynamics excellent growth prospects • ~5%1 share in German acute care Hospital market in Germany hospital ~12%1 share in Spanish private ~ € 109 bn hospital market • Quality i

  20. Slide 20: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

    Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Sales by Region Market Dynamics projects and provides services for health care facilities worldwide Telemedicine market in Europe Emerging Markets • Offers project development, plannin

  21. Slide 21: Group: Medium-term Growth Targets 2020 – 2023

    Fresenius Group: Medium-term Growth Targets 2020 – 2023 (CAGRs) 4 – 7% Organic sales growth (plus ~1% small to mid-size confirmed acquisitions) 5 – 9% Organic net income1 growth (plus ~1% small to mid-size acquisitions) confirmed 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA B

  22. Slide 22: Fresenius SE: Earnings-Linked Dividend Policy

    Fresenius SE: Earnings-Linked Dividend Policy € per share 0.88 0.84 0.80 Track record 0.75 28th consecutive 0.62 dividend increase 0.55 CAGR dividend increase +15% 0.44 0.42 2020 0.37 Pay-out Ratio: 0.32 Dividend Policy 0.25 0.29 27% Pay-out Ratio 0.23 Dividend growth aligned Dividend to EPS1 growth

  23. Slide 23: Fresenius Share & Shareholder Structure

    Fresenius Share & Shareholder Structure Share price development LTM Analyst recommendations Click to view our interactive share price tool Click to view downloadable set of the consensus data 140 Sell 6% 120 FRE Accumulate/Add/Buy/ 100 DAX Outperform/Overweight Equal-weight/Hold/ 80 Neutral 22% 72%

  24. Slide 24: FRE Historical share price performance

    FRE Historical share price performance April 2017 90 € Click to view our interactive share price tool Acquisition of Akorn and October 2018 Merck KGaA's biosimilars Fresenius confirms and 80 € business narrows Group guidance for FY18 70 € March 2020 Outbreak of COVID-19 pandemic 60 € December 2018 G

  25. Slide 25: Strategic update

    Agenda 01 03 04 Company 02 Financial review Attachments Highlights Q2/21 & Strategic Outlook FY/21 update Commerzbank Corporate Conference, August 31, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 25

  26. Slide 26: Key messages Q2/21

    Key messages Q2/21 Very strong performance Rebounding elective Cost & efficiency program: Guidance raised despite with dynamic sales and net procedures in all relevant First measures implemented; expected challenges in income growth markets Net income savings >€100 H2/21 million p.a. in 2023 expecte

  27. Slide 27: Group: Update cost & efficiency program

    Fresenius Group: Update cost & efficiency program • Wide-reaching operating model review; update in fall 2021 • Optimization of production network • FMC contribution to savings and • Reduction of product portfolio complexity expenses in timeframe 2021 to 2023 not • Centralization of worldwide purcha

  28. Slide 28: Fresenius Kabi: China's dynamic growth offsets softness in North America

    Fresenius Kabi: China’s dynamic growth more than offsets softness in North America; biosimilar business on track North America Europe & Latin America Asia Pacific Biosimilars Q2/21 still marked by fewer elective Healthy growth in Europe on the China with very strong organic Adalimumab received marke

  29. Slide 29: Fresenius Helios: Gradually increasing elective treatments in Germany

    Fresenius Helios: Gradually increasing elective treatments in Germany; excellent growth at Helios Spain based on activity levels above pre-pandemic levels in most medical areas Helios Germany Helios Spain Fertility Services Continuous upward trend in elective Excellent operating performance in Q2 Co

  30. Slide 30: Vamed: Business back to growth in Q2/21

    Fresenius Vamed: Business back to growth in Q2/21; momentum in H2/21 highly dependent on further development of COVID pandemic Update? Easing of COVID-19 headwinds in Q2/21 Project business – strong order book Project business shows signs of recovery – despite COVID-19 Excellent order intake in Q2/2

  31. Slide 31: Financial review Q2/21 & Outlook FY/21

    Agenda 01 02 04 Company Strategic update 03 Attachments Highlights Financial review Q2/21 & Outlook FY/21 Commerzbank Corporate Conference, August 31, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 31

  32. Slide 32: Q2/21 Profit and Loss Statement

    Q2/21 Profit and Loss Statement Sales EBIT +8% -4% Net Income Q2/21: €9,246 m Q2/21: €1,030 m +20% Income Tax Rate Net Interest Q2/21: €474 m 21.5% -€121 m Q2/20: 23.5% Q2/20: -€167 m All growth rates in constant currency (cc) Before special items Net income attributable to shareholders of Fresenius

  33. Slide 33: Q2/21 Business Segment Growth

    Q2/21 Business Segment Growth Organic sales growth EBIT growth (cc) +1% -29% +7% +7% +14% +51% 17% +223% +6% -4% All figures before special items For a detailed overview of special items please see the reconciliation tables provided on our website https://www.fresenius.com/results-center. Commerzban

  34. Slide 34: Q2/21 Cash Flow

    Q2/21 Cash Flow Operating CF Capex (net) Free Cash Flow1 €m Q2/2021 LTM Margin Q2/2021 LTM Margin Q2/2021 LTM Margin 921 14.2% -201 -5.3% 720 8.9% 197 14.3% -114 -8.5% 83 5.8% 223 11.0% -153 -5.9% 70 5.1% 58 3.9% -25 -3.6% 33 0.3% Corporate/Other 52 n.a. -6 n.a. 46 n.a. 656 12.9% -298 -6.8% 358 6.1%

  35. Slide 35: FY/21 Financial Outlook by Business Segment

    FY/21 Financial Outlook by Business Segment FY/20 H1/21 FY/21e €m (except otherwise stated) Base Actual FY/21e New Low-to-mid single- Sales growth (org) 6,976 5% Confirmed digit % Stable to low single- Low single- EBIT growth (cc) 1,095 4% digit % digit % Low-to-mid single- Mid single- Sales growth

  36. Slide 36: FY/21 Financial Guidance

    FY/21 Financial Guidance FY/20 H1/21 FY/21e €m (except otherwise stated) Base Actual FY/21e New Sales growth (cc) 36,277 6% Low-to-mid Confirmed single-digit % Net income growth (cc) 1,796 8% At least Low-single- broadly stable digit % Before special items and including estimated COVID-19 effects Ne

  37. Slide 37: Attachments

    Agenda 01 02 03 Company Strategic update Financial review 04 Highlights Q2/21 & Outlook FY/21 Attachments Commerzbank Corporate Conference, August 31, 2021 © Fresenius SE & Co. KGaA Investor Relations & Sustainability 37

  38. Slide 38: Fresenius Kabi: Q2 & H1/21 Organic Sales Growth by Regions

    Fresenius Kabi: Q2 & H1/21 Organic Sales Growth by Regions Δ YoY Δ YoY €m Q2/21 organic H1/21 organic North America 522 -6% 1,080 -8% Europe 634 10% 1,260 4% Emerging Markets 599 19% 1,176 23% Total sales 1,755 7% 3,516 5% Commerzbank Corporate Conference, August 31, 2021 © Fresenius SE & Co. KGaA I

  39. Slide 39: Fresenius Kabi: Q2 & H1/21 Organic Sales Growth by Product Segment

    Fresenius Kabi: Q2 & H1/21 Organic Sales Growth by Product Segment Δ YoY Δ YoY €m Q2/21 organic H1/21 organic IV Drugs 672 -5% 1,386 -4% Infusion Therapy 215 17% 411 8% Clinical Nutrition 530 18% 1,038 16% Medical Devices/ 338 15% 681 11% Transfusion Technology Total sales 1,755 7% 3,516 5% Commerzb

  40. Slide 40: Fresenius Kabi: Q2 & H1/21 EBIT Growth

    Fresenius Kabi: Q2 & H1/21 EBIT Growth €m Q2/21 Δ YoY cc H1/21 Δ YoY cc North America 162 -25% 336 -26% Margin 31.0% -830 bps 31.1% -770 bps Europe 98 23% 217 18% Margin 15.5% +140 bps 17.2% +180 bps Emerging Markets 156 50% 282 66% Margin 26.0% +510 bps 24.0% +620 bps Corporate and Corporate R&D -1

  41. Slide 41: Fresenius Helios: Q2 & H1/21 Key Financials

    Fresenius Helios: Q2 & H1/21 Key Financials €m Q2/21 Δ YoY cc H1/21 Δ YoY cc Total sales 2,738 14%1 5,387 9%1 Thereof Helios Germany 1,675 3%1 3,348 1%1 Thereof Helios Spain 1,020 38%1 1,996 24%1 Total EBIT 298 51% 566 20% Margin 10.9% +230 bps 10.5% +60 bps Thereof Helios Germany 152 3% 302 -3% Mar

  42. Slide 42: Fresenius Helios: Key Metrics

    Fresenius Helios: Key Metrics H1/21 FY/20 Δ No. of hospitals Germany 89 89 0% - Acute care hospitals 86 86 0% No. of hospitals Spain 53 52 2% (Hospitals) No. of beds Germany 29,957 29,978 0% - Acute care hospitals 29,419 29,451 0% No. of beds Spain 7,992 7,936 1% (Hospitals) Admissions Germany (acut

  43. Slide 43: Fresenius Vamed: Q2 & H1/21 Key Financials

    Fresenius Vamed: Q2 & H1/21 Key Financials €m Q2/21 Δ YoY cc H1/21 Δ YoY cc Total sales 556 17% 1,033 6% Thereof organic sales 17% 6% Project business 164 12% 278 -3% Service business 392 19% 755 10% Total EBIT 16 -- 12 -- Order intake1 713 -- 851 -- Order backlog1 3,635 19%2 1 Project business only

  44. Slide 44: Group: Calculation of Noncontrolling Interests

    Fresenius Group: Calculation of Noncontrolling Interests €m H1/21 H1/20 Earnings before tax and noncontrolling interests 1,781 1,907 Taxes -394 -440 Noncontrolling interests, thereof -477 -592 Fresenius Medical Care net income not attributable to Fresenius -320 -431 (H1/21: ~68%) Noncontrolling inte

  45. Slide 45: Group: Cash Flow

    Fresenius Group: Cash Flow €m Q2/21 LTM Margin Δ YoY Operating Cash Flow 1,451 12.9% -53% Capex (net) -499 -6.1% -5% Free Cash Flow 952 6.8% -63% (before acquisitions and dividends) Acquisitions (net) -456 Dividends -855 Free Cash Flow -359 -0.3% -115% (after acquisitions and dividends) Commerzbank

  46. Slide 46: Estimated COVID-19 Effects H1/21

    Estimated COVID-19 Effects H1/21 Growth cc Estimated Estimated as reported COVID-19 impact cc growth cc incl. COVID-19 excl. COVID-19 Q2/21 Q2/20 Q2/21 Q2/20 Q2/21 Q2/20 Sales 8% 2% 2% to 1% -4% to -5% 6% to 7% 6% to 7% Net income1 20% -13% 10% to 6% -13% to -17% 10% to 14% 0% to 4% Growth cc Estima

  47. Slide 47: Group: Proven Track Record of Deleveraging

    Fresenius Group: Proven Track Record of Deleveraging Net Debt/EBITDA1 Hospitals from 4 3.6x 3.6x 3 3.6x 3 3.5x 3.5 3,5 3.5x 3 3.2x 3.4x 3 3.1x 3.0x 3.0x 3.0x 3 2.8x 2.7x 2.7x 2.7x 2.6x 2.7x 2.5 2,5 2.6x 2.6x 2.2x 2.5x 2.3x 2.3x 2 2 2002 2003 2004 2005 Q1/06 2006 2007 2008 2009 2010 2011 2012 2013 20

  48. Slide 48: Group: Major long-term debt maturities

    1 Fresenius Group: Major long-term debt maturities €m Maturity 3,000 3.000 4.8 years on average 738 2.000 2,000 500 2,323 584 1,093 1,000 848 1.000 1,000 1,815 1,657 1,388 1,250 921 750 589 650 500 500 500 337 0 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 Fresenius Medical Care

  49. Slide 49: Sales by Business Segment – FX, Acquisitions/Divestitures Effects Q2/21

    Sales by Business Segment – FX, Acquisitions/Divestitures Effects Q2/21 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m Q2/21 Q2/20 rates effects rates growth tions Others Fresenius Medical Care 4,320 4,557 -5% -7% 2% 1% 1% 0% Fresenius Kabi 1,755 1,678 5

  50. Slide 50: Sales by Business Segment – FX, Acquisitions/Divestitures Effects H1/21

    Sales by Business Segment – FX, Acquisitions/Divestitures Effects H1/21 Growth at Currency Growth at Divesti- actual translation constant Organic Acquisi- tures/ €m H1/21 H1/20 rates effects rates growth tions Others Fresenius Medical Care 8,530 9,045 -6% -8% 2% 1% 1% 0% Fresenius Kabi 3,516 3,467 1

  51. Slide 51: Group: Solid Balance Sheet Structure

    Fresenius Group: Solid Balance Sheet Structure B/S total (€bn) 46.7 53.1 56.7 67.0 66.6 69.7 • Healthy Equity and Liability Split • Strong equity ratio of >40% on average 41% 40% 39% 39% 45% 44% • Equity ratio kept in narrow range despite rapid growth of Fresenius Group 36% 33% 41% 39% 39% 32% 23% 2

  52. Slide 52: Group: Financial Performance Indicators

    Fresenius Group: Financial Performance Indicators Growth Profitability Liqudity Capital efficiency Capital management Sales growth Operating income (EBIT) Operating cash flow EBIT Net debt (in constant currency) +/ - Financial result ÷ Sales Income taxes ÷ EBITDA Sales growth - Income taxes = Cash f

  53. Slide 53: Group: Performance Indicators 5-year overview

    Fresenius Group1: Performance Indicators 5-year overview Targets 20202 2020 2019 2018 2017 2016 Sales growth (in constant currency) +3% to +6% 5% 6% 6% 16% 6% Net income3 growth (in constant currency) -4% to +1% -3% 0% 7% 21% 13% Liquidity and capital management Cash flow margin 12% to 14% 18.1% 12.

  54. Slide 54: Business segments: Performance Indicators 5-year overview

    Business segments1: Performance Indicators 5-year overview Targets 20202 2020 2019 2018 2017 2016 Fresenius Medical Care Sales growth Mid-to-high single-digit (in constant currency) %-range 5% 5% 4% 9% 7% Net income growth 3,4 Mid-to-high single-digit (in constant currency) %-range 12% -2% 4% 7% 16%

  55. Slide 55: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar Contact 02 November 2021 Results Q3/21 Investor Relations & Sustainability Please note that these dates could be subject to change. Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: [email protected] For further information and current news:

Fresenius SE & Co. KGaA — Commerzbank Corporate Conference 2021 on 6ix